TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06173518: A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin L

Sponsor: Autolus Limited · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$1,727,880

Rescue Site Savings

+$1,130,976

Unlock Full NCT06173518 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06173518 Rescue Dossier →